An abnormal MoCA means further evaluation is appropriate; it does not diagnose dementia or Alzheimer's disease. The usual next steps are a detailed history, assessment of daily function, medication and health review, laboratory tests, and often brain imaging. The MoCA, or Montreal Cognitive Assessment, is a brief screen of memory and other thinking skills. Its publisher states that clinicians must not rely on it alone to diagnose cognitive disease, so the score should start a clinical investigation rather than settle the question (MoCA Cognition's terms of use).
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does an abnormal MoCA score mean?
- The next appointment focuses on changes in real life
- Clinicians look for conditions that can mimic dementia
- What can MRI or CT show?
- When are specialists and Alzheimer's biomarkers useful?
What does an abnormal MoCA score mean?
A score below 26 out of 30 can signal possible cognitive impairment. The 2025 Alzheimer's Association guideline adds one point for people with fewer than 12 years of education and directs clinicians to consider history and everyday function alongside the result (the Alzheimer's Association assessment guideline). The cutoff is not a dividing line between healthy aging and dementia.
Education, language, sensory difficulties, health problems, and the circumstances of testing can affect how a score should be interpreted. The pattern of missed items may also matter. Difficulty with recall raises different questions from problems with attention, language, planning, or visual-spatial tasks, but none of these patterns establishes a diagnosis by itself.
The next appointment focuses on changes in real life
The clinician should ask when the changes began, whether they appeared gradually or suddenly, and how they have progressed. A person who knows the patient well can provide important examples that the patient may not notice or remember.
Expect questions about tasks such as managing medicines, paying bills, preparing meals, navigating familiar places, keeping appointments, or handling household responsibilities. These details help distinguish a low test score from cognitive impairment that is affecting independent daily life. Useful preparation includes:.
- Bring the MoCA score and the date and setting of the test.
- Write down several specific changes, including when each began.
- Note whether symptoms fluctuate or follow a steady course.
- Bring a complete list of prescriptions, nonprescription medicines, and supplements.
- Ask someone familiar with the changes to attend, if possible.
Clinicians look for conditions that can mimic dementia
The evaluation should cover mood, sleep, alcohol use, medical history, and all medicines. It also usually includes physical and neurologic examinations. Depression, sleep apnea, delirium, medication effects, thyroid disease, and vitamin deficiencies can resemble dementia, and some may be treatable.
Routine laboratory testing helps identify contributing medical problems. The specific tests should reflect the person's symptoms and health history rather than treating the MoCA score as proof of a brain disease. Timing matters. A sudden or sharply fluctuating change is different from a gradual decline, so report the course clearly instead of describing every problem simply as "memory loss.".
What can MRI or CT show?
The Alzheimer's Association recommends a basic laboratory panel and structural brain imaging for nearly all patients with a cognitive-behavioral syndrome—meaning concerning changes in thinking, behavior, or both. Non-contrast MRI is preferred, while CT is an alternative when MRI is unavailable or unsuitable (the 2025 DETeCD-ADRD guideline). Imaging can reveal or help exclude tumors, hydrocephalus, strokes, and other structural conditions.
Patterns of brain shrinkage may support a suspected neurodegenerative cause. An MRI or CT scan cannot establish Alzheimer's disease on its own. Its value lies in combining structural findings with the history, functional changes, examination, laboratory results, and cognitive testing.
When are specialists and Alzheimer's biomarkers useful?
Referral to neurology, geriatrics, or neuropsychology is appropriate when the diagnosis remains unclear, symptoms are unusual, onset occurs at a younger age, or behavioral or psychiatric changes dominate. Referral may also be reasonable when the patient or family wants a more detailed evaluation. Neuropsychological testing examines several thinking abilities in greater depth than the MoCA.
A specialist may then consider Alzheimer's biomarkers, including amyloid PET, cerebrospinal-fluid tests, or selected blood tests, when identifying the underlying cause would affect diagnosis or treatment decisions. These tests are not substitutes for the clinical evaluation. The FDA-cleared Lumipulse blood test is intended for symptomatic adults aged 55 or older in specialized care; false results remain possible, and the FDA says it is neither a screening test nor a stand-alone diagnostic test (the FDA's 2025 clearance notice).
